Multiple Myeloma: all 3,712 studies

Page 20 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.

• Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell TransplantActive, not recruitingNCT05271630
• Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001#CompletedNCT05270928Phase 1
• Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002#Status unknownNCT05266768Phase 1
• MargheRITA (Remote Intelligence for Therapeutic Adherence)CompletedNCT05260203Not applicable
• A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT05259839Phase 1
• Biomarkers in Multiple MyelomaActive, not recruitingNCT05259553Not applicable
• A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT05257083Phase 3
• Plasma-free Replacement in Patients With Multiple MyelomaCompletedNCT05251896Not applicable
• A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple MyelomaCompletedNCT05243342Phase 1
• Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)No longer availableNCT05238311
• A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaStatus unknownNCT05236621Phase 3
• Sequential Therapy in Multiple Myeloma Guided by MRD AssessmentsActive, not recruitingNCT05231629Phase 2
• Study of ORIC-533 in Relapsed or Refractory Multiple MyelomaCompletedNCT05227144Phase 1
• Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCTStatus unknownNCT05218603
• A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class ExposureCompletedNCT05217082
• Financial Difficulty in Patients With Blood CancerCompletedNCT05212233
• Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple MyelomaActive, not recruitingNCT05208086
• Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell TherapyWithdrawnNCT05204160Phase 2
• A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple MyelomaStatus unknownNCT05201118Phase 1
• Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple MyelomaSuspendedNCT05199311Phase 1/2
• Cost-Utility Analysis of Home-based Versus Hospital-based Chemotherapy in Multiple Myeloma: Case of CarfilzomibStatus unknownNCT05184595Not applicable
• A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple MyelomaWithdrawnNCT05183139Phase 4
• FT576 in Subjects With Multiple MyelomaCompletedNCT05182073Phase 1
• Iberdomide Maintenance Therapy in Patients With Multiple MyelomaActive, not recruitingNCT05177536Phase 2
• PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple MyelomaTerminatedNCT05172596Phase 2
• Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple MyelomaWithdrawnNCT05170789Phase 2
• Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)Approved for marketingNCT05164250
• Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma.CompletedNCT05163405
• Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)No longer availableNCT05161598
• Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLLTerminatedNCT05153330Phase 1
• B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple MyelomaStatus unknownNCT05150522Phase 1/2
• A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal ImpairmentStatus unknownNCT05147493Phase 2
• Telehealth Exercise Intervention to Improve Physical Function and Frailty in Multiple Myeloma SurvivorsCompletedNCT05142371Not applicable
• A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple MyelomaCompletedNCT05139225Phase 1
• The BurnAlong Pilot Study for Adolescent and Young Adult Cancer SurvivorsCompletedNCT05131815Not applicable
• Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)Active, not recruitingNCT05130827Phase 2
• Isa-RVD Study in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT05123131Phase 2
• Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse EventsCompletedNCT05123001
• Survival Outcomes of Multiple Myeloma Patients Admitted on Assiut Clinical Hematology UnitStatus unknownNCT05119205
• Isatuximab in Type I CryoglobulinemiaStatus unknownNCT05114109Phase 2
• Descartes-25 in Relapsed/Refractory Multiple MyelomaTerminatedNCT05113342Phase 1
• Impact of Chemotherapeutic Treatments in Patients Aged 75 Years and Over Treated for Lymphoid Hematological MalignancyCompletedNCT05101759Not applicable
• A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MMStatus unknownNCT05088330Not applicable
• A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Phase 3
• Stem Cell Translpantation in Multiple MyelomaCompletedNCT05082675Phase 2
• A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)Status unknownNCT05066646Phase 1/2
• A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple MyelomaStatus unknownNCT05066022Not applicable
• Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple MyelomaTerminatedNCT05065047Phase 1
• Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T TherapyCompletedNCT05064787Not applicable
• Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to LenalidomideActive, not recruitingNCT05060627Phase 1/2
• Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT StudyCompletedNCT05053100
• Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MMStatus unknownNCT05052970Phase 1
• Marizomib Central Nervous System (CNS)WithdrawnNCT05050305Phase 2
• A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple MyelomaActive, not recruitingNCT05050097Phase 1
• Biology and Genetics of Smouldering MyelomaStatus unknownNCT05047107
• Feasibility Study of an ePRO Monitoring for Patients With Multiple Myeloma and Development of Item ListsCompletedNCT05036863
• A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple MyelomaActive, not recruitingNCT05028348Phase 3
• Ph I Study in Adult Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT05027594Phase 1
• Study of Oral LOXO-338 in Patients With Advanced Blood CancersCompletedNCT05024045Phase 1
• TriPRIL CAR T Cells in Multiple MyelomaActive, not recruitingNCT05020444Phase 1
• A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple MyelomaActive, not recruitingNCT05016778Early Phase 1
• Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple MyelomaWithdrawnNCT05013437Early Phase 1
• A Study of NINLARO® in Chinese Adults With Multiple MyelomaActive, not recruitingNCT05013190
• A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple MyelomaCompletedNCT05011097Phase 1
• Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple MyelomaStatus unknownNCT05008536Early Phase 1
• A Study of KRN125 in Patients With Multiple Myeloma and Malignant LymphomaCompletedNCT05007652Phase 2
• Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple MyelomaStatus unknownNCT05006469Phase 3
• Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple MyelomaActive, not recruitingNCT05002816Phase 1/2
• Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT05000450Phase 1/2
• A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."Active, not recruitingNCT04998786Phase 2
• A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)WithdrawnNCT04998747Phase 1
• Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received LenalidomideStatus unknownNCT04989140Phase 4
• A Study of Real Life Treatment for Multiple Myeloma (MM)Active, not recruitingNCT04985643
• Stepping Up: A Trial of Activity Monitoring Devices in Patients Undergoing Autologous Stem Cell TransplantCompletedNCT04985409Not applicable
• Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to DrugsWithdrawnNCT04985357
• Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04984434Phase 1
• SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood CancerActive, not recruitingNCT04977024Phase 2
• Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Active, not recruitingNCT04975997Phase 3
• Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT04975399Phase 1
• A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone)Active, not recruitingNCT04965155Phase 2
• P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple MyelomaActive, not recruitingNCT04960579Phase 1
• Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple MyelomaTerminatedNCT04956302Phase 1
• Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing SurgerySuspendedNCT04955808
• REST - Replacing Steroids in the Transplant IneligbleCompletedNCT04939844Phase 2
• Study of FasT CAR-T GC012F Injection in High Risk TE NDMM PatientsStatus unknownNCT04935580Phase 1/2
• MInimal Residual Disease Adapted StrategyActive, not recruitingNCT04934475Phase 3
• Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple MyelomaActive, not recruitingNCT04933539Phase 2
• A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial TherapyActive, not recruitingNCT04923893Phase 3
• A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple MyelomaWithdrawnNCT04918511Phase 1
• Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY DiseaseTerminatedNCT04912427Phase 1
• Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple MyelomaTerminatedNCT04895410Phase 1
• Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple MyelomaTerminatedNCT04892264Phase 1
• Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMMActive, not recruitingNCT04891809Phase 2
• Selinexor in Combination With Thalidomide and Dexamethasone in RRMMStatus unknownNCT04891744Phase 1/2
• Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AMLTerminatedNCT04887259Phase 1
• Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04883242Phase 2
• Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell TransplantActive, not recruitingNCT04876248Phase 2
• Immunomonitoring and Multiple Myeloma: Impact of Lenalidomide on Immune Checkpoint ExpressionCompletedNCT04872023Not applicable
• Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple MyelomaWithdrawnNCT04864522Phase 1/2
• Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple MyelomaStatus unknownNCT04861480Phase 1

← Multiple Myeloma overview